Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.

Date publication

mai 2015

Journal

Inflammatory bowel diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25803504

Résumé

In case of a loss of response to adalimumab, some patients with Crohn's disease may derive benefit from increasing the dosing frequency to 40 mg weekly. Efficacy and safety of adalimumab 80 mg weekly remain unknown.

Mots clés

Adalimumab, therapeutic use, Adult, Anti-Inflammatory Agents, therapeutic use, Crohn Disease, drug therapy, Female, Follow-Up Studies, Humans, Male, Prognosis, Prospective Studies, Remission Induction, Safety

Référence

Inflamm. Bowel Dis.. 2015 May;21(5):1047-53